// App-Quantinova.ai

: THE AUTOPHAGY INHIBITOR HYDROXYCHLOROQUINE ADDED TO THALIDOMIDE BASED THERAPY FOR MULTIPLE MYELOMA DEEPENS RESPONSE AND PROLONGS REMISSION IN PATIENTS PREVIOUSLY TREATED WITH THALIDOMIDE.

Researchers

Presenter

  • Stephen O'mara

Principal Investigators

  • N/A

Medical Centers

  • New England Northwest Haematology,Tamworth,Australia;Tamara Hospital,Tamworth,Australia;Haematology,Laverty pathology,Tamworth,Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Thalidomide

  • Bortezomib

  • Plaquenil

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved